FDA Adverse Event Injury Summary report: N

PROLENE POLYPROPYLENE MESH

MDR report key: 3132505 · Received May 29, 2013

Report

Report Number
2210968-2013-05981
Event Type
Injury
Date Received
May 29, 2013
Report Date
May 9, 2013
Manufacturer
ETHICON, INC.
Product Code
FTL
PMA / PMN Number
K962530
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 1

(B)(4). CONCLUSION: NO CONCLUSION CAN BE DRAWN AT THIS TIME. SHOULD ADDITIONAL INFORMATION BE OBTAINED, A SUPPLEMENTAL 3500A FORM WILL BE SUBMITTED ACCORDINGLY. IN ADDITION, A REVIEW OF THE BATCH MANUFACTURING RECORDS WAS CONDUCTED AND THE BATCH MET ALL FINISHED GOODS RELEASE CRITERIA.

Additional Manufacturer Narrative · 1

(B)(4). ADDITIONAL NARRATIVE: IT WAS REPORTED THAT ON (B)(6) 2013, THE MESH WAS REMOVED AND REPLACED. SINCE THEN, THE PAIN, DISCOMFORT AND INFECTIONS HAVE GONE AWAY. (B)(4).

Description of Event or Problem · 1

IT WAS REPORTED THAT A PATIENT UNDERWENT A LOWER INGINUAL HERNIA REPAIR PROCEDURE ON (B)(6) 2005 AND MESH WAS IMPLANTED. THE PATIENT BEGAN EXPERIENCING DISCOMFORT SHORTLY AFTER THE PROCEDURE AND IS NOW EXPERIENCING REPEATED INFECTIONS. THE PATIENT WENT TO A PAIN MANAGEMENT CLINIC, BUT AFTER STOPPING, CONTINUED TO EXPERIENCE INTERMITTENT DISCOMFORT FOR SEVERAL YEARS. IT WAS A NEUROPATHIC-TYPE PAIN IN THE LEFT GROIN WITH INTERMITTENT SWELLING, PARASTHESIA AND PAIN. HE RESPONDED TO INJECTIONS AND NEURONTIN 300MG 3X DAILY. ABOUT TWO YEARS AGO, THE DISCOMFORT INCREASED AND THE PATIENT STARTED HAVING REDNESS AND SWELLING IN THE SURGICAL AREA. THE PATIENT HAD REPEATEDLY BEEN PLACED ON ANTIBIOTICS FOR INFECTIONS. THE PATIENT HAS BEEN TOLD THAT THE MESH NEEDS TO BE REMOVED. THE PRIMARY CARE PHYSICIAN OPINES THAT IT IS LIKELY THAT THE MESH OR SCAR TISSUE HAS CAUSED ENTRAPMENT OF A NERVE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
237463 PROLENE POLYPROPYLENE MESH MESH, SURGICAL, POLYMERIC FTL ETHICON, INC. NA UBB053

Patients

Seq Age Sex Outcome Treatment
1 53 YR Required Intervention